<code id='71555986CF'></code><style id='71555986CF'></style>
    • <acronym id='71555986CF'></acronym>
      <center id='71555986CF'><center id='71555986CF'><tfoot id='71555986CF'></tfoot></center><abbr id='71555986CF'><dir id='71555986CF'><tfoot id='71555986CF'></tfoot><noframes id='71555986CF'>

    • <optgroup id='71555986CF'><strike id='71555986CF'><sup id='71555986CF'></sup></strike><code id='71555986CF'></code></optgroup>
        1. <b id='71555986CF'><label id='71555986CF'><select id='71555986CF'><dt id='71555986CF'><span id='71555986CF'></span></dt></select></label></b><u id='71555986CF'></u>
          <i id='71555986CF'><strike id='71555986CF'><tt id='71555986CF'><pre id='71555986CF'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          hotspot

          author:leisure time    - browse:2
          translucent 3D DNA helix with blue and purple background
          Adobe

          Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

          The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

          advertisement

          “We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus